View:
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 1, 2007
NEOSTEM, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-10909 22-2343568
-------- ------- ----------
(State Or Other (Commission (IRS Employer
Jurisdiction Of File Number) Identification No.)
Incorporation)
420 Lexington Avenue, Suite 450
New York, New York 10170
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212)-584-4180
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
<PAGE>
Item 7.01. Regulation FD Disclosure.
NeoStem, Inc. (the "Company"), is furnishing presentation materials,
included as Exhibit 99.1 to this current report and incorporated into this item
by reference, which will be used by the Company at the Acumen BioFin Rodman and
Renshaw Healthcare Conference on November 5, 2007.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit 99.1 Presentation to Investors
<PAGE>
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
NEOSTEM, INC.
By: /s/ Catherine M. Vaczy
----------------------------------------
Catherine M. Vaczy
Vice President and General Counsel
Dated: November 1, 2007
Exhibit
99.1
1 NeoStem
Investor Overview Robin Smith, MD, MBA CEO and Chairman of the Board (AMEX:
NBS)
2
Title: FORWARD LOOKING STATEMENTS Body: This presentation contains
“forward-looking statements” within the meaning of the Private Securities
Litigation Reform Act of 1995. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors which may
cause
the actual results, performance or achievements of NeoStem, or industry results,
to be materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. When used in
this presentation, statements that are not statements of current or historical
fact may be deemed to be forward-looking statements. Additionally,
statements concerning: the Company’s ability to develop the adult stem cell
business, the future of regenerative medicine and the role of adult stem
cells
in that future, the future use of adult stem cells as a treatment option
and the
potential revenue growth of such business are forward-looking
statements. The Company’s ability to enter the adult stem cell arena
and future operating results are dependent upon many factors
including but not limited to (i) the Company’s ability to obtain
sufficient capital or a strategic business arrangement to fund its expansion
plans; (ii) the Company’s ability to build the management and human resources
and infrastructure necessary to support the growth of its business and obtain
appropriate state and other licenses; (iii) competitive factors and developments
beyond the Company's control; (iv) scientific and medical developments
beyond the Company’s control, (v) our inability to obtain appropriate
state licenses or any other adverse effect or limitations caused by government
regulation of the business; whether any of the Coompany’s current or future
patent applications result in issued patents; and (vii) other risk factors
discussed in the Company’s periodic filings with the Securities and Exchange
Commission which are available for review at www.sec.gov under “Search for
Company Filings.” You are cautioned not to place undue reliance
on these forward looking statements, which speak only as of the date
hereof.
3
Body: The Stem Cell Therapy Landscape Platform Business Why Should a Person
Collect Today? How Our Platform Differs From Cord Blood Industry Our Broad
Market Recent Events Our Revenue Model The Team Capital Structure Investor
Considerations Agenda
Title:
Projected U.S. Stem Cell Therapy Sales 4 Source: Robert
Young, RRY Publications, February 2006 $8.58 by 2016 Stem
Cell Therapy: A $20 billion worldwide market by 2010 --Frost &
Sullivan
5
Title: 70+ Diseases Treated w/Stem Cells Results for many have been quite
encouraging
6
Title: Virtually All Therapeutic Areas Body: New Therapies could be on the
Market in 5-10 Years Autoimmune Diabetes/Metabolic Cardiovascular
Orthopedic (Gp:) Fracture (Gp:) 2 Months Post
BMSC Over 750 Adult Stem Cell Clinical Trials Over 240 Specific
to Autologous Use
7
Title: 131 Cardiovascular Clinical Trials Reference. clinicaltrials.gov One
Indication Only!
8
Title: Platform Business Body: NeoStem has a safe and non invasive way for
adults to have their stem cells collected today and stored for future
use. Our platform will allow doctors and patients ready access to
their cells as the therapies become available in the future.
9
Title: Why Should a Person Collect Today Body: Finding an ostensively
“matching” donor is very difficult People are dying on the “wait list” (4 mo.
avg.) Rejection-Graft vs. Host Disease (40% chance even if “perfect”
match) Risk of transmission of communicable disease Possible
reluctance to collect and use autologous cells once you are sick because
they
may have become compromised Inverse relationship between age versus quality
and
quantity of cells Financing available from GE contributing to affordability
Banking Your Own Cells with NeoStem Before You Get Sick Solves these
Issues
10
Title: Our Platform Differs From Cord Blood Industry
11
Title: A Broad Target Market Body: People with family history of
disease; Patients in a pre-disease or early-disease states; Parents who have
banked their children’s cord blood; First responders military personnel
Policemen, firemen; EMS Industry (workers facing exposure to
radiation/chemicals) By 2010, it is estimated that 39% of the
U.S. population (over 110 mm people) will be 45 years of age or older—a time
when the incidence of age-related diseases begin to
accelerate.
12
Title: Recent Events Body: Closed on $6,350,000 Listed on the American Stock
Exchange Launched Las Vegas Signed multi-center agreement initially to expand
in
Midwest with Stem Collect, LLC founded by James Doty, MD, former CEO of $1B
Nasdaq Medical Device Co. Accuray Signed agreement for New York facility
with
large physician practice, ProHealth Executed
collaborative agreement with New England Cryogenic Center, one of the largest
cryopreservation facilities in the country for stem cell and other tissue
storage
13
Title: Our Revenue ModelBody: Current: Collection Center FeesCollection from
patientsProcessing patient cellsStorage (recurring revenue)Potential:Utilization
feesSupplier of cellsCollection fees for trialsGovernment/military contractsSBIR
grantsLicensing of technology
14
Title: NeoStem Management & Senior StaffBody: Robin Smith, M.D., MBA, Chief
Executive Officer and Chairman of the Board. Dr. Smith has acted as a
senior advisor and investor to both publicly traded and privately
held companies where she has played a significant role in
restructuring and/or growing the companies. Dr. Smith also serves on the
Board
of Trustees of the NYU School of Medicine Foundation (becoming the NYU Medical
Center Board) and Chairman of the Board of Directors for the New York University
Hospital for Joint Diseases and was appointed to the Chemotherapy Foundation
Board of Trustees, the New York Theatre Ballet and Choose
Living. Prior to these activities, Dr. Smith served as President
& Chief Executive Officer of IP2M. During her term, the company
was selected as being one of the 10 fastest growing technology companies
in
Houston.Mark Weinreb, Director and President. Former Owner, Bio Health
Laboratories.Larry A. May, Chief Financial Officer. Former Treasurer,
Amgen (NASDAQ: AMGN).Renee Cohen, MBA, Vice President. Operations and
Corporate Strategy. Formerly held senior executive positions at
Pfizer, Co-Founder and Chief Operating Officer of Drugvoice and was a strategic
consultant for Accenture’s Life Sciences Group. Catherine M. Vaczy, VP &
General Counsel. Former VP and Associate General Counsel, ImClone
(NASDAQ: IMCL) Denis Rodgerson, Ph.D., Director of Stem Cell
Science. Founder of NeoStem, Former Founder of StemCyte, Former Head
of Clinical Chemistry and Toxicology and Clinical Laboratory Computing, UCLA
Medical Center.George Smith, M.D., Medical Director of Laboratory Operations
in
California. Among his many distinguished career accomplishments, Dr
Smith is cofounder of UCLA Bone Marrow Transplant Center.Arlene Graime, Director
Government Affairs & Special Projects. Former Senior Director of
Marketing at Coach, Inc., served as the National Director of Events for the
United States Olympic Committee and worked with key staff members of two
White
House administrations.Kevin Mannix, Director of Sales. Former
principle manager in sales at Baxter Healthcare, Vested Healthcare Management
and Turner Consulting with 27 years of experience in healthcare.Julio C.
Guerra,
M.D., ABP, Director of Marketing. Former Senior VP of Marketing and
New Program Development of Anthrogeneis, which was bought by Celgene; formerly
with Gerber, Ross Products and Mead Johnson.
15
Title: Scientific Advisory Board Body: Wayne A. Marasco, M.D.,
Ph.D. Chairman Chairman of Scientific Advisory
Board. Associate Professor-Department of Cancer and Immunology &
AIDS at the Dana-Farber Cancer Institute and Associate Professor of Medicine
at
Harvard Medical School. He is taking the lead in expanding the
Company’s academic relationships and research collaborations. Douglas W.
Losordo, MD For many years a Professor of Medicine at Tufts
University School of Medicine and Chief of Cardiovascular Research at St.
Elizabeth’s Medical Center in Boston, Dr. Losordo was recently appointed
Professor of Medicine at Northwestern University and Director of the Feinberg
Cardiovascular Research Institute and Program in Cardiovascular Regenerative
Medicine. A Fellow or Member of many national professional organizations,
he
currently serves on committees of the American College of Cardiology, the
American Diabetes Association and the American Society of Gene Therapy where
he
chairs the Cardiovascular Gene Therapy Committee. Dr. Losordo serves as
Principal Investigator in many grant research projects and has published
widely,
contributing to more than 300 professional articles, abstracts and book chapters
in recent years. He also serves on the Editorial Boards of numerous medical
specialty journals including Stem Cells, Vascular Medicine and Circulation
Research. Stephen D. Nimer, MD Dr. Nimer is
Professor of Medicine and Professor of Pharmacology at Weill Medical College
of
Cornell University. He also serves as Chief of Hematology Service and
Head of the Division of Hematologic Oncology at Memorial Sloan-Kettering
Cancer
Center in New York City. Dr. Nimer is a member of many national
professional organizations, including the American Society of Hematology,
the
American Society of Clinical Oncology, and the International Society for
Stem
Cell Research. He serves as a Reviewer for major medical journals, including
the
New England Journal of Medicine and the Journal of the American Medical
Association (JAMA) among many others. He serves on numerous national
and international Grant Review Committees and is a prominent invited speaker
at
conferences on his areas of expertise. He has authored or co-authored nearly
200
peer-reviewed papers, reviews, editorials and textbook chapters, primarily
focused on issues concerning hematology and oncology.
16
Title: Advisory BoardBody: Ron Rothenberg MD, FACEP Dr. Rothenberg is
a Fellow of the American College of Emergency Physicians (FACEP) and is the
founder of the California HealthSpan Institute in Encinitas, California.
He was
the 10th M.D. in the world to become fully board certified by the American
Board
of Anti-Aging Medicine. A graduate of Columbia University, College of Physicians
and Surgeons, and a specialist in Emergency Medicine at Los Angeles County-USC
Medical Center, he has served as Clinical Professor of Preventive and Family
Medicine at the UCSD School of Medicine Clinical Facility. He is currently
Attending Physician at Scripps Memorial Hospital in Encinitas.Douglas Wynyard
Mr. Douglas Wynyard is a Senior Vice President for Nordblom Company, a
full-service commercial real estate firm headquartered in the Boston
area. Mr. Wynyard has worked in the field of commercial real estate
for more than thirty years and has been associated with Nordblom Company
since
1986. He is experienced in real estate development, asset management,
leasing, investment sales, and marketing. He also represents numerous
corporations with the planning, acquisition and disposition of their
facilities. Having received a Bachelor’s degree in Zoology from
Bristol University, Mr. Wynyard is passionate about the biological sciences
and
is an investor in a number of medtech companies.Richard Gatti, MD Dr.
Richard Gatti, a professor at the University of California, Los Angeles (UCLA)
and renowned Pathologist at the UCLA Medical Center, was one of the early
pioneers of bone marrow transplantation, among the earliest known forms of
adult
stem cell therapeutics, for immunodeficiency in the late sixties. Dr. Gatti
is
also a leading authority in the field of gene therapeutics and has authored
or
co-authored hundreds of papers related to the molecular identification and
treatment of genetic disorders. He has worked for many years to help find
a cure
for Ataxia-Telangiectasia, a progressive neurological disorder of childhood,
associated with increased cancer risk, immunodeficiency, radiosensitivity,
and
cell cycle defects. Neil Livingstone, PhD Dr. Livingstone is
currently the Chairman and Chief Executive Officer of ExecutiveAction LLC.
He
was the founder and, until January, 2007, Chief Executive Officer of
GlobalOptions Inc., which went public in 2005. He is also Lead
Director of Erickson Air-Crane, a $200 million helicopter
company. Dr. Livingstone has noted expertise on national security,
and is the author of nine books on terrorism. He has served on advisory panels
to The Secretary of State, The Chief of Naval Operations, and The Pentagon.
He
has testified before Congress and delivered more than 500 major addresses
in the
U.S. and abroad, including recent speeches at The House of Commons and The
United Nations. Dr. Livingstone serves on numerous advisory boards, including
Supercom Inc., Digital Ally, the Africa Society, and No Greater
Love. He was a Founding Member and Incorporator of the Solidarity
Endowment, formed in the West to promote the goals of Polish Solidarity.
He was
the Founder and Chairman of the Institute on Terrorism and Sub-national Conflict
and served as President of Watergate South for more than seven years.Bradford
Billet, OBE CEM Mr. Billet is an executive with the City of New York, where
his
responsibilities include matters of international affairs, security and
emergency management. He is also chairman of the Billet Group, a
management consulting company. Mr. Billet’s company assists its clients on a
full range of issues, not related to City of New York. During the past 20
plus
years, Mr. Billet has acquired extensive experience in International Affairs,
Emergency Management, Security, Governmental and Business Management,
Administration and Operational disciplines. He has held high-ranking positions
in both the private and public sectors with budgets in excess of 180 million
dollars. Mr. Billet has responded, coordinated and directed multi agency
emergency operations, including the September 11th attacks and the 1993 bombing
of the World Trade Center, 20 aviation accidents as well as numerous manmade
and
natural disasters, involving mass casualties and/or
fatalities.
17
Title: Capitalization
18
Title: Investor ConsiderationsBody: Building product pipeline that would
appeal
to a large pharmaceutical companyAmgenBoston
ScientificCelgeneGenzymeTevaPerkinElmer/Viacell ($300 million
acquisition)Proprietary Technology Recurring revenue/inexpensive source of
cash
flowCreating a brand as a new form of health protection: ”Bio-Insurance”Look to
move up the value chain
19
Title: QuestionsBody: Robin Smith, MD MBAChairman & CEODirect: (212)
584-4174Email: rsmith@neostem.com NeoStem, Inc.420 Lexington AvenueSuite
450New
York, NY 10170Main: (212) 584-4180Fax: (646) 514-7787www.neostem.com 1.888.STEM
BANK